Pembrolizumab versus Ipilimumab in Advanced Melanoma

Robert, Caroline; Schachter, Jacob; V. Long, Georgina; Arance, Ana; Grob, Jean‐Jacques; Mortier, Laurent; Daud, Adil; S. Carlino, Matteo; M. McNeil, Catriona; Lotem, Michal; Larkin, James; Lorigan, Paul; Neyns, Bart; U. Blank, Christian; Hamid, Omid; Mateus, Christine; Shapira‐Frommer, Ronnie; Kosh, Michele; Zhou, Honghong; Ibrahim, Nageatte; Ebbinghaus, Scot; Ribas, Antoni

doi:10.1056/nejmoa1503093

Public

Pembrolizumab versus Ipilimumab in Advanced Melanoma

Published in New England Journal of Medicine • Apr 19, 2015

Authors:

Caroline Robert

Jacob Schachter

Georgina V. Long

Abstract

BACKGROUND: The immune checkpoint inhibitor ipilimumab is the standard-of-care treatment for patients with advanced melanoma. Pembrolizumab inhibits the programmed cell death 1 (PD-1) immune checkpoint and has antitumor activity in patients with advanced melanoma. METHODS: In this randomized, contro...

Subject

Pembrolizumab

Ipilimumab

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!